Cancer Research Targets Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perner, S.
Right arrow Articles by Rubin, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perner, S.
Right arrow Articles by Rubin, M. A.
[Cancer Research 66, 8337-8341, September 1, 2006]
© 2006 American Association for Cancer Research

Priority Reports

TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer

Sven Perner1,2,4, Francesca Demichelis1,2,6, Rameen Beroukhim2,3,7, Folke H. Schmidt1,2, Juan-Miguel Mosquera1,2, Sunita Setlur1,2, Joelle Tchinda1,2, Scott A. Tomlins8, Matthias D. Hofer1,2, Kenneth G. Pienta9,10, Rainer Kuefer5, Robert Vessella11, Xiao-Wei Sun1,2, Matthew Meyerson2,3,7, Charles Lee1,2, William R. Sellers2,3,7, Arul M. Chinnaiyan8,9 and Mark A. Rubin1,2,3

1 Department of Pathology, Brigham and Women's Hospital; 2 Harvard Medical School; 3 Dana-Farber Cancer Institute, Boston, Massachusetts; 4 Department of Pathology, University of Ulm; 5 Department of Urology, University Hospital Ulm, Ulm, Germany; 6 Bioinformatics Group, SRA Division, ITC-irst, Trento, Italy; 7 Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of 8 Pathology, 9 Urology, and 10 Medical Oncology, University of Michigan, Ann Arbor, Michigan; and 11 University of Washington, Seattle, Washington

Requests for reprints: Mark A. Rubin, Department of Pathology, Brigham and Women's Hospital/Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115-6110. Phone: 617-525-6700; Fax: 617-264-6898; E-mail: marubin{at}partners.org.

Prostate cancer is a common and clinically heterogeneous disease with marked variability in progression. The recent identification of gene fusions of the 5'-untranslated region of TMPRSS2 (21q22.3) with the ETS transcription factor family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4 (17q21), suggests a mechanism for overexpression of the ETS genes in the majority of prostate cancers. In the current study using fluorescence in situ hybridization (FISH), we identified the TMPRSS2:ERG rearrangements in 49.2% of 118 primary prostate cancers and 41.2% of 18 hormone-naive lymph node metastases. The FISH assay detected intronic deletions between ERG and TMPRSS2 resulting in TMPRSS2:ERG fusion in 60.3% (35 of 58) of the primary TMPRSS2:ERG prostate cancers and 42.9% (3 of 7) of the TMPRSS2:ERG hormone-naive lymph node metastases. A significant association was observed between TMPRSS2:ERG rearranged tumors through deletions and higher tumor stage and the presence of metastatic disease involving pelvic lymph nodes. Using 100K oligonucleotide single nucleotide polymorphism arrays, a homogeneous deletion site between ERG and TMPRSS2 on chromosome 21q22.2-3 was identified with two distinct subclasses distinguished by the start point of the deletion at either 38.765 or 38.911 Mb. This study confirms that TMPRSS2:ERG is fused in approximately half of the prostate cancers through deletion of genomic DNA between ERG and TMPRSS2. The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement. (Cancer Res 2006; 66(17): 8337-41)




This article has been cited by other articles:


Home page
 Cancer Res.Home page
I. N. Holcomb, J. M. Young, I. M. Coleman, K. Salari, D. I. Grove, L. Hsu, L. D. True, M. P. Roudier, C. M. Morrissey, C. S. Higano, et al.
Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer
Cancer Res., October 1, 2009; 69(19): 7793 - 7802.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Rodig, M. Mino-Kenudson, S. Dacic, B. Y. Yeap, A. Shaw, J. A. Barletta, H. Stubbs, K. Law, N. Lindeman, E. Mark, et al.
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Clin. Cancer Res., August 15, 2009; 15(16): 5216 - 5223.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cai, H. Wang, Y. Xu, S. Chen, and S. P. Balk
Reactivation of Androgen Receptor-Regulated TMPRSS2:ERG Gene Expression in Castration-Resistant Prostate Cancer
Cancer Res., August 1, 2009; 69(15): 6027 - 6032.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zong, L. Xin, A. S. Goldstein, D. A. Lawson, M. A. Teitell, and O. N. Witte
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
PNAS, July 28, 2009; 106(30): 12465 - 12470.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-M. Mosquera, R. Mehra, M. M. Regan, S. Perner, E. M. Genega, G. Bueti, R. B. Shah, S. Gaston, S. A. Tomlins, J. T. Wei, et al.
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States
Clin. Cancer Res., July 15, 2009; 15(14): 4706 - 4711.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. S. Rickman, D. Pflueger, B. Moss, V. E. VanDoren, C. X. Chen, A. de la Taille, R. Kuefer, A. K. Tewari, S. R. Setlur, F. Demichelis, et al.
SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation-Specific Fusion Transcript in Prostate Cancer
Cancer Res., April 1, 2009; 69(7): 2734 - 2738.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gopalan, M. A. Leversha, J. M. Satagopan, Q. Zhou, H. A. Al-Ahmadie, S. W. Fine, J. A. Eastham, P. T. Scardino, H. I. Scher, S. K. Tickoo, et al.
TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
Cancer Res., February 15, 2009; 69(4): 1400 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. D. Hofer, R. Kuefer, C. Maier, K. Herkommer, S. Perner, F. Demichelis, T. Paiss, W. Vogel, M. A. Rubin, and J. Hoegel
Genome-Wide Linkage Analysis of TMPRSS2-ERG Fusion in Familial Prostate Cancer
Cancer Res., January 15, 2009; 69(2): 640 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. P. Clark, K. W. Munson, J. W. Gu, K. Lamparska-Kupsik, K. G. Chan, J. S. Yoshida, M. H. Kawachi, L. E. Crocitto, T. G. Wilson, Z. Feng, et al.
Performance of a Single Assay for Both Type III and Type VI TMPRSS2:ERG Fusions in Noninvasive Prediction of Prostate Biopsy Outcome
Clin. Chem., December 1, 2008; 54(12): 2007 - 2017.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Q. Lu, E. Nunez, C. Lin, K. Christensen, T. Downs, D. A. Carson, J. Wang-Rodriguez, and Y.-T. Liu
A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants
Nucleic Acids Res., November 1, 2008; 36(20): e130 - e130.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Wang, Y. Cai, W. Yu, C. Ren, D. M. Spencer, and M. Ittmann
Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts
Cancer Res., October 15, 2008; 68(20): 8516 - 8524.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Han, R. Mehra, S. M. Dhanasekaran, J. Yu, A. Menon, R. J. Lonigro, X. Wang, Y. Gong, L. Wang, S. Shankar, et al.
A Fluorescence In situ Hybridization Screen for E26 Transformation-Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer
Cancer Res., September 15, 2008; 68(18): 7629 - 7637.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Kawamata, S. Ogawa, M. Zimmermann, B. Niebuhr, C. Stocking, M. Sanada, K. Hemminki, G. Yamatomo, Y. Nannya, R. Koehler, et al.
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray
PNAS, August 19, 2008; 105(33): 11921 - 11926.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Frohling and H. Dohner
Chromosomal Abnormalities in Cancer
N. Engl. J. Med., August 14, 2008; 359(7): 722 - 734.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
G Attard, J E Ang, D Olmos, and J S de Bono
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development
J. Clin. Pathol., August 1, 2008; 61(8): 891 - 896.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Smith
Rapid Testosterone Cycling and Chemotherapy for Prostate Cancer: A Way Forward or Return to the Past?
J. Clin. Oncol., June 20, 2008; 26(18): 2932 - 2933.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. R. Setlur, K. D. Mertz, Y. Hoshida, F. Demichelis, M. Lupien, S. Perner, A. Sboner, Y. Pawitan, O. Andren, L. A. Johnson, et al.
Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer
J Natl Cancer Inst, June 4, 2008; 100(11): 815 - 825.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-M. Mosquera, S. Perner, E. M. Genega, M. Sanda, M. D. Hofer, K. D. Mertz, P. L. Paris, J. Simko, T. A. Bismar, G. Ayala, et al.
Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications
Clin. Cancer Res., June 1, 2008; 14(11): 3380 - 3385.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L.J. Tammela, and T. Visakorpi
TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis
Clin. Cancer Res., June 1, 2008; 14(11): 3395 - 3400.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mehra, S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan
Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer
Cancer Res., May 15, 2008; 68(10): 3584 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra
Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies
Endocr. Rev., April 1, 2008; 29(2): 234 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
F. Demichelis, H. Greulich, J. A. Macoska, R. Beroukhim, W. R. Sellers, L. Garraway, and M. A. Rubin
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines
Nucleic Acids Res., April 1, 2008; 36(7): 2446 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Klezovitch, M. Risk, I. Coleman, J. M. Lucas, M. Null, L. D. True, P. S. Nelson, and V. Vasioukhin
A causal role for ERG in neoplastic transformation of prostate epithelium
PNAS, February 12, 2008; 105(6): 2105 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
S. Jhavar, A. Reid, J. Clark, Z. Kote-Jarai, T. Christmas, A. Thompson, C. Woodhouse, C. Ogden, C. Fisher, C. Corbishley, et al.
Detection of TMPRSS2-ERG Translocations in Human Prostate Cancer by Expression Profiling Using GeneChip Human Exon 1.0 ST Arrays
J. Mol. Diagn., January 1, 2008; 10(1): 50 - 57.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
F. Demichelis and M. A Rubin
TMPRSS2-ETS fusion prostate cancer: biological and clinical implications
J. Clin. Pathol., November 1, 2007; 60(11): 1185 - 1186.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
A. B Rajput, M. A Miller, A. De Luca, N. Boyd, S. Leung, A. Hurtado-Coll, L. Fazli, E. C Jones, J. B Palmer, M. E Gleave, et al.
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
J. Clin. Pathol., November 1, 2007; 60(11): 1238 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Lapointe, C. Li, C. P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J. D. Brooks, and J. R. Pollack
Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis
Cancer Res., September 15, 2007; 67(18): 8504 - 8510.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mehra, B. Han, S. A. Tomlins, L. Wang, A. Menon, M. J. Wasco, R. Shen, J. E. Montie, A. M. Chinnaiyan, and R. B. Shah
Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases
Cancer Res., September 1, 2007; 67(17): 7991 - 7995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel, and J. A. Schalken
Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer
Clin. Cancer Res., September 1, 2007; 13(17): 5103 - 5108.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.